[go: up one dir, main page]

MX2009006672A - Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. - Google Patents

Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.

Info

Publication number
MX2009006672A
MX2009006672A MX2009006672A MX2009006672A MX2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A
Authority
MX
Mexico
Prior art keywords
topiramate
ondansetron
alcohol consumption
combined effects
drugs
Prior art date
Application number
MX2009006672A
Other languages
English (en)
Inventor
Bankole A Johnson
Nassima Ait-Daoud Touririne
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of MX2009006672A publication Critical patent/MX2009006672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con el uso de combinaciones de fármacos para el tratamiento de trastornos adictivos. En forma más específica, la presente invención se relaciona con el uso de drogas junto con la intervención conductual para tratar enfermedades y trastornos relacionados con el alcohol así como para el tratamiento de la obesidad y la regulación del peso corporal.
MX2009006672A 2006-12-19 2007-12-19 Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. MX2009006672A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87566806P 2006-12-19 2006-12-19
US89852807P 2007-01-31 2007-01-31
US93103107P 2007-05-21 2007-05-21
PCT/US2007/088100 WO2008077092A2 (en) 2006-12-19 2007-12-19 Combined effects of topiramate and ondansetron on alcohol consumption

Publications (1)

Publication Number Publication Date
MX2009006672A true MX2009006672A (es) 2009-10-26

Family

ID=39537067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006672A MX2009006672A (es) 2006-12-19 2007-12-19 Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.

Country Status (8)

Country Link
US (1) US20100041689A1 (es)
EP (2) EP2556830A1 (es)
JP (1) JP2010513569A (es)
AU (1) AU2007333656A1 (es)
CA (1) CA2673481A1 (es)
CR (1) CR10938A (es)
MX (1) MX2009006672A (es)
WO (1) WO2008077092A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
MX2010009509A (es) 2008-02-28 2010-11-30 Univ Virginia Gen transportador de serotonina y tratamiento de alcoholismo.
WO2010065930A1 (en) 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
RU2393868C1 (ru) * 2009-05-08 2010-07-10 Надежда Дмитриевна Агаркина Способ лечения алкогольной зависимости
US20110224196A1 (en) * 2010-01-07 2011-09-15 Vivus, Inc. Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
UA116615C2 (uk) 2010-07-02 2018-04-25 Юніверсіті Оф Вірджінія Петент Фаундейшн Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
US20130072516A1 (en) * 2011-09-07 2013-03-21 Eagle Advancement Institute Llc Method of alcohol cessation and treatment
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
CN114903134A (zh) 2014-12-09 2022-08-16 以西结·戈兰 酒精饮料替代品
DK3230255T3 (da) 2014-12-09 2020-06-22 Ezekiel Golan Regulatorer af uhæmmet adfærd
BR112017020307B1 (pt) 2015-03-26 2023-11-07 Jacqueline M. Iversen Usos de uma combinação de naproxeno e fexofenadina
JP7549576B2 (ja) * 2018-11-06 2024-09-11 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイドアンタゴニストを送達するための組成物及び方法
JP7749463B2 (ja) * 2019-05-02 2025-10-06 クローズド ループ メディスン リミテッド システム及び方法
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
US12420014B2 (en) 2023-06-05 2025-09-23 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (es) 1972-04-20 1978-08-31 Merz & Co
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
CZ20013061A3 (cs) 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů
US6656122B2 (en) * 2000-09-29 2003-12-02 New Health Sciences, Inc. Systems and methods for screening for adverse effects of a treatment
US7122308B2 (en) * 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) * 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
US20030100479A1 (en) * 2001-08-21 2003-05-29 Dow David J. Gene polymorphisms and response to treatment
US20060173064A1 (en) 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) * 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
CN2722428Y (zh) 2004-07-21 2005-08-31 上海正贝照明电器有限公司 镇流器内藏式一体化节能灯
PT1928438E (pt) * 2005-09-26 2013-04-03 Avigen Inc Método para tratamento de dependências de drogas e comportamentos
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US20080228698A1 (en) * 2007-03-16 2008-09-18 Expanse Networks, Inc. Creation of Attribute Combination Databases
WO2009026381A2 (en) * 2007-08-21 2009-02-26 University Of Virginia Patent Foundation Method, computer program product and system for individual assessment of alcohol sensitivity
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
MX2010009509A (es) * 2008-02-28 2010-11-30 Univ Virginia Gen transportador de serotonina y tratamiento de alcoholismo.
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
CA2760675A1 (en) * 2009-05-01 2010-11-04 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism

Also Published As

Publication number Publication date
WO2008077092A8 (en) 2009-08-20
WO2008077092A2 (en) 2008-06-26
EP2124909A2 (en) 2009-12-02
CA2673481A1 (en) 2008-06-26
JP2010513569A (ja) 2010-04-30
EP2124909A4 (en) 2010-03-31
WO2008077092A3 (en) 2008-08-14
CR10938A (es) 2010-01-11
US20100041689A1 (en) 2010-02-18
EP2556830A1 (en) 2013-02-13
AU2007333656A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
MX2009006672A (es) Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
WO2011083150A3 (en) Obesity small molecules
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
AU2011328009A8 (en) Compounds and methods for treating pain
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2010004074A (es) Combinacion 059.
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
MY151018A (en) Use of nutritional compositions for preventing disorders
WO2007084818A3 (en) Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
PH12013501490A1 (en) Methods for diagnosing and treating eye-length related disorders
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
NZ600858A (en) Suture line administration technique using botulinum toxins
WO2010080756A3 (en) Harmine derivatives for reducing body weight
MX343326B (es) Metodos para mejorar el metabolismo energetico.
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
WO2008147483A3 (en) Neurogenic compounds
MY150931A (en) Substituted oxazolidinones and their use

Legal Events

Date Code Title Description
HH Correction or change in general